DK1760088T3 - Tumor associerede peptider, der bindes promiskuöst til human leuko-cyt-antigen (HLA) klasse II-molekyler - Google Patents
Tumor associerede peptider, der bindes promiskuöst til human leuko-cyt-antigen (HLA) klasse II-molekylerInfo
- Publication number
- DK1760088T3 DK1760088T3 DK05019254T DK05019254T DK1760088T3 DK 1760088 T3 DK1760088 T3 DK 1760088T3 DK 05019254 T DK05019254 T DK 05019254T DK 05019254 T DK05019254 T DK 05019254T DK 1760088 T3 DK1760088 T3 DK 1760088T3
- Authority
- DK
- Denmark
- Prior art keywords
- molecules
- tumour
- present
- relates
- hla
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05019254A EP1760088B1 (en) | 2005-09-05 | 2005-09-05 | Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1760088T3 true DK1760088T3 (da) | 2008-06-09 |
Family
ID=35170099
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK07007914.0T DK1806358T3 (da) | 2005-09-05 | 2005-09-05 | Tumorassocierede peptider, der bindes promiskuøst til Humant Leukocyt-Antigen (HLA) klasse II molekyler |
| DK07007915.7T DK1806359T3 (da) | 2005-09-05 | 2005-09-05 | Tumorassocierede peptider, der bindes promiskuøst til Humant Leukocyt-Antigen (HLA) klasse II molekyler |
| DK05019254T DK1760088T3 (da) | 2005-09-05 | 2005-09-05 | Tumor associerede peptider, der bindes promiskuöst til human leuko-cyt-antigen (HLA) klasse II-molekyler |
| DK09011319.2T DK2135878T3 (da) | 2005-09-05 | 2006-09-05 | Tumor-associerede peptider, der bindes promiskuøst til Humant Leukocyt-Antigen (HLA) klasse II molekyler |
| DK06791838.3T DK1922335T3 (da) | 2005-09-05 | 2006-09-05 | Tumorassocierede peptider, der bindes promiskuøst til Humant Leukocyt-Antigen (HLA) klasse II molekyler |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK07007914.0T DK1806358T3 (da) | 2005-09-05 | 2005-09-05 | Tumorassocierede peptider, der bindes promiskuøst til Humant Leukocyt-Antigen (HLA) klasse II molekyler |
| DK07007915.7T DK1806359T3 (da) | 2005-09-05 | 2005-09-05 | Tumorassocierede peptider, der bindes promiskuøst til Humant Leukocyt-Antigen (HLA) klasse II molekyler |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK09011319.2T DK2135878T3 (da) | 2005-09-05 | 2006-09-05 | Tumor-associerede peptider, der bindes promiskuøst til Humant Leukocyt-Antigen (HLA) klasse II molekyler |
| DK06791838.3T DK1922335T3 (da) | 2005-09-05 | 2006-09-05 | Tumorassocierede peptider, der bindes promiskuøst til Humant Leukocyt-Antigen (HLA) klasse II molekyler |
Country Status (23)
| Country | Link |
|---|---|
| US (6) | US10196432B2 (da) |
| EP (6) | EP1760088B1 (da) |
| JP (1) | JP5627180B2 (da) |
| KR (3) | KR101386827B1 (da) |
| CN (3) | CN105440119A (da) |
| AT (5) | ATE461214T1 (da) |
| AU (2) | AU2006289290B2 (da) |
| BR (1) | BRPI0615462A2 (da) |
| CA (2) | CA2929252A1 (da) |
| CY (5) | CY1107973T1 (da) |
| DE (4) | DE602005020046D1 (da) |
| DK (5) | DK1806358T3 (da) |
| EA (1) | EA013876B1 (da) |
| ES (5) | ES2341295T3 (da) |
| HK (2) | HK1183678A1 (da) |
| HR (2) | HRP20100128T1 (da) |
| NO (1) | NO340870B1 (da) |
| NZ (2) | NZ566104A (da) |
| PL (5) | PL1806358T3 (da) |
| PT (5) | PT1806358E (da) |
| SI (5) | SI1806358T1 (da) |
| UA (1) | UA98295C2 (da) |
| WO (1) | WO2007028574A2 (da) |
Families Citing this family (90)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE461214T1 (de) * | 2005-09-05 | 2010-04-15 | Immatics Biotechnologies Gmbh | Tumor-assoziierte peptide, welche an unterschiedliche menschliche leukozytenantigene der klasse ii binden |
| US20090004213A1 (en) * | 2007-03-26 | 2009-01-01 | Immatics Biotechnologies Gmbh | Combination therapy using active immunotherapy |
| KR101290892B1 (ko) | 2007-07-27 | 2013-07-31 | 이매틱스 바이오테크놀로지스 게엠베하 | 신경 및 뇌 종양에 대한 신규 면역요법 |
| HUE025636T2 (en) | 2007-07-27 | 2016-04-28 | Immatics Biotechnologies Gmbh | New immunogenic epitope for immunotherapy |
| UA103882C2 (uk) | 2007-07-27 | 2013-12-10 | Імматікс Біотекнолоджіс Гмбх | Композиція пухлино-асоційованих пептидів та відповідна протиракова вакцина |
| ES2632123T3 (es) | 2007-08-20 | 2017-09-11 | Oncotherapy Science, Inc. | Péptido CDH3 y agente medicinal que comprende el mismo |
| CA2704397C (en) | 2007-11-01 | 2018-01-23 | Mayo Foundation For Medical Education And Research | Hla-dr binding peptides and their uses |
| DK2105501T3 (da) | 2008-03-27 | 2015-11-23 | Immatics Biotechnologies Gmbh | Hidtil ukendt immunterapi mod neuronale tumorer og hjernetumorer |
| ATE462442T1 (de) * | 2008-04-30 | 2010-04-15 | Immatics Biotechnologies Gmbh | Neuartige formulierungen von tumor-assoziierten peptiden, welche an menschliche leukozytenantigene der klasse i oder ii für impfungen binden |
| EP2119726B2 (en) | 2008-05-14 | 2017-11-29 | Immatics Biotechnologies GmbH | Novel and powerful MHC-class II peptides derived from survivin and neurocan |
| TW201008574A (en) | 2008-08-19 | 2010-03-01 | Oncotherapy Science Inc | INHBB epitope peptides and vaccines containing the same |
| DK2172211T3 (da) * | 2008-10-01 | 2015-02-16 | Immatics Biotechnologies Gmbh | Sammensætning af tumorassocierede peptider og relateret anticancervaccine til behandling af glioblastom (GBM) og andre cancertyper |
| CA2748937C (en) | 2009-01-28 | 2016-07-19 | Industrial Technology Research Institute | Urine and serum biomarkers associated with diabetic nephropathy |
| WO2011073215A2 (en) | 2009-12-14 | 2011-06-23 | Immatics Biotechnologies Gmbh | Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof |
| GB201004551D0 (en) * | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer |
| GB201004575D0 (en) | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers |
| GB201009222D0 (en) | 2010-06-02 | 2010-07-21 | Immatics Biotechnologies Gmbh | Improved cancer therapy based on tumour associated antigens derived from cyclin D1 |
| NZ609916A (en) | 2010-12-14 | 2015-03-27 | Immatics Biotechnologies Gmbh | Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof |
| WO2012129514A1 (en) * | 2011-03-23 | 2012-09-27 | Fred Hutchinson Cancer Research Center | Method and compositions for cellular immunotherapy |
| PL3456339T3 (pl) | 2013-08-05 | 2022-03-21 | Immatics Biotechnologies Gmbh | Nowa immunoterapia przeciwko szeregu nowotworom, takim jak rak płuc, w tym nsclc |
| TWI819228B (zh) * | 2013-08-05 | 2023-10-21 | 德商伊瑪提克斯生物科技有限公司 | 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物（八） |
| GB201319446D0 (en) | 2013-11-04 | 2013-12-18 | Immatics Biotechnologies Gmbh | Personalized immunotherapy against several neuronal and brain tumors |
| GB201408255D0 (en) * | 2014-05-09 | 2014-06-25 | Immatics Biotechnologies Gmbh | Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML) |
| IL248203A0 (en) | 2014-05-09 | 2016-11-30 | Immatics Biotechnologies Gmbh | Innovative immunotherapy against blood tumors such as acute leukemia in the spinal cord |
| GB201411037D0 (en) | 2014-06-20 | 2014-08-06 | Immatics Biotechnologies Gmbh | Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemai (CLL) |
| HUE056607T2 (hu) | 2014-12-23 | 2022-02-28 | Immatics Biotechnologies Gmbh | Új peptidek és peptidkombinációk, hepatocelluláris karcinóma (HCC) és más rákok elleni immunoterápiában történõ alkalmazásra |
| GB201501017D0 (en) | 2014-12-23 | 2015-03-04 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers |
| GB201505305D0 (en) * | 2015-03-27 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel Peptides and combination of peptides for use in immunotherapy against various tumors |
| GB201505585D0 (en) | 2015-03-31 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers |
| GB201507030D0 (en) | 2015-04-24 | 2015-06-10 | Immatics Biotechnologies Gmbh | Immunotherapy against lung cancers, in particular NSCLC |
| GB201507719D0 (en) | 2015-05-06 | 2015-06-17 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers |
| NL2014935B1 (en) | 2015-06-08 | 2017-02-03 | Applied Immune Tech Ltd | T cell receptor like antibodies having fine specificity. |
| PE20230321A1 (es) * | 2015-07-01 | 2023-02-22 | Immatics Biotechnologies Gmbh | Nuevos peptidos y nuevas combinaciones de peptidos para el uso en la inmunoterapia contra el cancer de ovario y otros tipos de cancer |
| GB201511546D0 (en) | 2015-07-01 | 2015-08-12 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
| CN107912043B (zh) | 2015-07-06 | 2022-02-18 | 伊玛提克斯生物技术有限公司 | 用于食管癌和其他癌症免疫治疗的新型肽和肽组合物 |
| GB201512369D0 (en) | 2015-07-15 | 2015-08-19 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers |
| GB201513921D0 (en) | 2015-08-05 | 2015-09-23 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers |
| UA125817C2 (uk) | 2015-08-28 | 2022-06-15 | Імматікс Біотекнолоджіс Гмбх | Пептид, придатний для лікування та/або діагностики раку |
| MY198087A (en) | 2015-10-05 | 2023-07-31 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers |
| IL298653A (en) | 2015-12-11 | 2023-01-01 | Immatics Biotechnologies Gmbh | New peptides and a combination of peptides for use in immunotherapy against several types of cancer |
| RU2729116C2 (ru) | 2015-12-16 | 2020-08-04 | Гритстоун Онколоджи, Инк. | Идентификация, производство и применение неоантигенов |
| GB201522667D0 (en) * | 2015-12-22 | 2016-02-03 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers |
| GB201602918D0 (en) | 2016-02-19 | 2016-04-06 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers |
| GB201603568D0 (en) * | 2016-03-01 | 2016-04-13 | Immatics Biotechnologies Gmbh | Efficient treatment options including peptides and combination of peptide and cell based medicaments for use in immunotherapy against urinary bladder cancer |
| IL302705A (en) | 2016-03-01 | 2023-07-01 | Immatics Biotechnologies Gmbh | Peptides, combinations of peptides, cell-based drugs for use in immunotherapy against bladder cancer and other types of cancer |
| GB201603987D0 (en) | 2016-03-08 | 2016-04-20 | Immatics Biotechnologies Gmbh | Uterine cancer treatments |
| EP3436048A4 (en) * | 2016-03-31 | 2019-11-27 | Neon Therapeutics, Inc. | NEOANTIGENES AND METHODS OF USE |
| MX2018012152A (es) | 2016-04-06 | 2019-02-07 | Immatics Biotechnologies Gmbh | Nuevos peptidos y nuevas combinaciones de peptidos para el uso en la inmunoterapia contra la leucemia mieloide aguda (aml) y otros tipos de cancer. |
| WO2017182395A1 (en) | 2016-04-21 | 2017-10-26 | Immatics Biotechnologies Gmbh | Immunotherapy against melanoma and other cancers |
| SG10202006117QA (en) | 2016-04-21 | 2020-08-28 | Immatics Biotechnologies Gmbh | Immunotherapy against melanoma and other cancers |
| JP7075125B2 (ja) | 2016-05-25 | 2022-05-25 | イマティクス バイオテクノロジーズ ゲーエムベーハー | 標的としてのおよび胆嚢がんおよび胆管がんおよびその他のがんに対する免疫療法で使用するための新規ペプチド、ペプチド組み合わせ |
| RU2630647C1 (ru) * | 2016-05-27 | 2017-09-11 | Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства | ГУМАНИЗИРОВАННОЕ АНТИТЕЛО К КОНФОРМАЦИОННОМУ ЭПИТОПУ С3 КОМПОНЕНТА КОМПЛЕМЕНТА ЧЕЛОВЕКА, ПОСЛЕДОВАТЕЛЬНОСТЬ ДНК (ВАРИАНТЫ), ЭКСПРЕССИОННЫЙ ВЕКТОР, СОДЕРЖАЩИЙ ПОСЛЕДОВАТЕЛЬНОСТЬ ДНК (ВАРИАНТЫ), И ШТАММ КЛЕТОК ЯИЧНИКОВ КИТАЙСКОГО ХОМЯЧКА CHO-humC34-ПРОДУЦЕНТ ДАННОГО ГУМАНИЗИРОВАННОГО АНТИТЕЛА |
| CA3026180A1 (en) * | 2016-06-10 | 2017-12-14 | Gadeta B.V. | Human leukocyte antigen restricted gamma delta t cell receptors and methods of use thereof |
| TWI796299B (zh) | 2016-08-26 | 2023-03-21 | 德商英麥提克生物技術股份有限公司 | 用於頭頸鱗狀細胞癌和其他癌症免疫治療的新型肽和支架 |
| NZ754222A (en) | 2016-12-08 | 2022-02-25 | Immatics Biotechnologies Gmbh | T cell receptors with improved pairing |
| DE102016123893A1 (de) | 2016-12-08 | 2018-06-14 | Immatics Biotechnologies Gmbh | T-Zellrezeptoren mit verbesserter Bindung |
| EP4035675A3 (en) | 2017-01-27 | 2022-11-16 | Immatics Biotechnologies GmbH | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
| AR110857A1 (es) | 2017-01-27 | 2019-05-08 | Immatics Biotechnologies Gmbh | Péptidos y combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de ovario y otros tipos de cáncer |
| WO2018138257A1 (en) | 2017-01-27 | 2018-08-02 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
| EP3576767A4 (en) * | 2017-02-06 | 2020-12-02 | Academia Sinica | RECOMBINANT PROTEINS AND USES THEREOF |
| KR20190137858A (ko) | 2017-04-10 | 2019-12-11 | 이매틱스 바이오테크놀로지스 게엠베하 | 백혈병 및 다른 암에 대한 면역요법에 사용하기 위한 펩티드 및 펩티드의 조합 |
| US11427614B2 (en) | 2017-04-10 | 2022-08-30 | Immatics Biotechnologies Gmbh | Peptides and combination thereof for use in the immunotherapy against cancers |
| WO2018189152A2 (en) | 2017-04-10 | 2018-10-18 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against leukemias and other cancers |
| MX2019012225A (es) | 2017-04-10 | 2019-12-09 | Immatics Biotechnologies Gmbh | Peptidos y combinaciones de los mismos para el uso en la inmunoterapia contra diversos tipos de cancer. |
| US10800823B2 (en) | 2017-07-07 | 2020-10-13 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers |
| SG11201913302SA (en) | 2017-07-07 | 2020-01-30 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against lung cancer, including nsclc, sclc and other cancers |
| WO2019055082A1 (en) | 2017-09-18 | 2019-03-21 | S & P Ingredient Development, Llc | LOW SODIUM SALT SUBSTITUTE COMPRISING POTASSIUM CHLORIDE |
| AU2018348165A1 (en) | 2017-10-10 | 2020-05-21 | Gritstone Bio, Inc. | Neoantigen identification using hotspots |
| US11885815B2 (en) | 2017-11-22 | 2024-01-30 | Gritstone Bio, Inc. | Reducing junction epitope presentation for neoantigens |
| DE102018108996B4 (de) | 2018-02-09 | 2021-10-21 | Immatics US, Inc. | Verfahren zur Herstellung autologer T-Zellen |
| AU2019218093A1 (en) | 2018-02-09 | 2020-09-10 | Immatics US, Inc. | Methods for manufacturing T cells |
| DE102018107224A1 (de) | 2018-02-21 | 2019-08-22 | Immatics Biotechnologies Gmbh | Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten |
| AU2019227813B2 (en) * | 2018-02-27 | 2024-06-27 | Gritstone Bio, Inc. | Neoantigen identification with pan-allele models |
| EP3539562A1 (en) * | 2018-03-12 | 2019-09-18 | Eberhard Karls Universität Tübingen Medizinische Fakultät | Immunotherapeutic peptides |
| TW202016131A (zh) | 2018-05-16 | 2020-05-01 | 德商英麥提克生物技術股份有限公司 | 用於抗癌免疫治療的肽 |
| US10925947B2 (en) | 2018-06-29 | 2021-02-23 | Immatics Biotechnologies Gmbh | A*03 restricted peptides for use in immunotherapy against cancers and related methods |
| TW202019955A (zh) | 2018-07-31 | 2020-06-01 | 德商英麥提克生物技術股份有限公司 | B*07 限制肽和肽組合的抗癌免疫治療和相關方法 |
| US11945850B2 (en) | 2018-09-17 | 2024-04-02 | Immatics Biotechnologies Gmbh | B*44 restricted peptides for use in immunotherapy against cancers and related methods |
| TW202024121A (zh) | 2018-09-18 | 2020-07-01 | 德商英麥提克生物技術股份有限公司 | A*01 限制肽和肽組合物在抗癌免疫治療中的用途和相關方法 |
| TW202039535A (zh) | 2018-12-18 | 2020-11-01 | 德商英麥提克生物技術股份有限公司 | B*08限制肽和肽組合物抗癌免疫治療和相關方法 |
| KR102215578B1 (ko) * | 2019-03-28 | 2021-02-15 | 한국과학기술연구원 | 인간 백혈구 항원에 특이적으로 결합하는 펩타이드 및 이의 용도 |
| SG11202112561UA (en) | 2019-06-06 | 2021-12-30 | Immatics Biotechnologies Gmbh | Sorting with counter selection using sequence similar peptides |
| CN110305209B (zh) * | 2019-07-09 | 2022-09-13 | 福建医科大学附属第一医院 | 用于治疗恶性肿瘤的多肽及其作为疫苗的用途 |
| CN114555815A (zh) * | 2019-07-30 | 2022-05-27 | 大学健康网络 | T细胞受体及其使用方法 |
| US11891427B2 (en) | 2020-09-29 | 2024-02-06 | Immatics Biotechnologies Gmbh | Amidated peptides and their deamidated counterparts displayed by non-HLA-a*02 for use in immunotherapy against different types of cancers |
| DE102020125465A1 (de) | 2020-09-29 | 2022-03-31 | Immatics Biotechnologies Gmbh | Amidierte Peptide und ihre deamidierten Gegenstücke, die durch nicht-HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten |
| DE102020125457A1 (de) | 2020-09-29 | 2022-03-31 | Immatics Biotechnologies Gmbh | Amidierte Peptide und ihre deamidierten Gegenstücke, die durch HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten |
| TW202241925A (zh) | 2021-01-15 | 2022-11-01 | 德商英麥提克生物技術股份有限公司 | 用於不同類型癌症免疫治療的ｈｌａ展示肽 |
| WO2024077601A1 (en) * | 2022-10-14 | 2024-04-18 | Guangdong Tcrcure Biopharma Technology Co., Ltd. | Peptide vaccines against glioma and uses thereof |
| CN117720620A (zh) * | 2023-12-13 | 2024-03-19 | 无锡市儿童医院 | 小分子多肽和其药物组合物、其制药用途 |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8211999B2 (en) * | 1970-02-11 | 2012-07-03 | Immatics Biotechnologies Gmbh | Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules |
| US8212000B2 (en) * | 1970-02-11 | 2012-07-03 | Immatics Biotechnologies Gmbh | Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules |
| US8258260B2 (en) * | 1970-02-11 | 2012-09-04 | Immatics Biotechnologies Gmbh | Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules |
| US4440859A (en) | 1977-05-27 | 1984-04-03 | The Regents Of The University Of California | Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms |
| GR66050B (da) * | 1977-09-20 | 1981-01-14 | Licinvest Ag | |
| US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
| NZ192465A (en) | 1978-12-22 | 1983-09-30 | Biogen Nv | Recombinant dna molecule comprising gene coding for polypeptide displaying hbv (hepatitis b virus) antigenicity usesthereof |
| US4530901A (en) | 1980-01-08 | 1985-07-23 | Biogen N.V. | Recombinant DNA molecules and their use in producing human interferon-like polypeptides |
| US4678751A (en) | 1981-09-25 | 1987-07-07 | Genentech, Inc. | Hybrid human leukocyte interferons |
| US4766075A (en) | 1982-07-14 | 1988-08-23 | Genentech, Inc. | Human tissue plasminogen activator |
| US4582800A (en) | 1982-07-12 | 1986-04-15 | Hoffmann-La Roche Inc. | Novel vectors and method for controlling interferon expression |
| US4757006A (en) | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
| US4677063A (en) | 1985-05-02 | 1987-06-30 | Cetus Corporation | Human tumor necrosis factor |
| US4810648A (en) | 1986-01-08 | 1989-03-07 | Rhone Poulenc Agrochimie | Haloarylnitrile degrading gene, its use, and cells containing the gene |
| US4810781A (en) | 1987-01-15 | 1989-03-07 | The George Washington University | Methods of preparing epitopes of tumor associated antigens |
| CA2132859A1 (en) * | 1992-04-03 | 1993-10-14 | Michael D. Pierschbacher | Decorin fragments and methods of inhibiting cell regulatory factors |
| CA2142007C (en) * | 1992-08-11 | 2007-10-30 | Robert Glen Urban | Immunomodulatory peptides |
| CA2175380A1 (en) * | 1993-10-29 | 1995-05-04 | Lan Bo Chen | A novel tumor marker and novel method of isolating same |
| AUPM322393A0 (en) | 1993-12-24 | 1994-01-27 | Austin Research Institute, The | Mucin carbohydrate compounds and their use in immunotherapy |
| CN1180843C (zh) | 1994-07-27 | 2004-12-22 | 昆士兰医学研究所 | 多表位疫苗 |
| UY24367A1 (es) * | 1995-11-23 | 2000-10-31 | Boehringer Ingelheim Int | Vacunas contra tumores y procedimiento para su produccion |
| US6805861B2 (en) | 1996-01-17 | 2004-10-19 | Imperial College Innovations Limited | Immunotherapy using cytotoxic T lymphocytes (CTL) |
| US6610821B1 (en) * | 1996-07-12 | 2003-08-26 | Mcgill University | Compounds and methods for modulating endothelial cell adhesion |
| EP0988385A2 (en) * | 1997-01-21 | 2000-03-29 | Human Genome Sciences | Tace-like and matrilysin-like polypeptides |
| US6316213B1 (en) * | 1997-03-19 | 2001-11-13 | The Board Of Trustees Of The University Of Arkansas | Methods for the early diagnosis of ovarian, breast and lung cancer |
| ATE302273T1 (de) * | 1997-10-15 | 2005-09-15 | Pharis Biotec Gmbh | Cadherin derived growth factor und seine verwendung |
| DE19757250A1 (de) * | 1997-12-22 | 1999-07-01 | Forssmann Wolf Georg Prof Dr | Insulin-like growth factor binding protein und seine Verwendung |
| US6746852B1 (en) * | 1998-05-08 | 2004-06-08 | Osi Pharmaceuticals, Inc. | AGS proteins and nucleic acid molecules and uses thereof |
| DE19936563A1 (de) | 1999-08-04 | 2001-02-08 | Boehringer Ingelheim Int | Tumorassoziiertes Antigen |
| DE19938583A1 (de) | 1999-08-18 | 2001-02-22 | Buehler Ag | Verfahren und Vorrichtung zur Herstellung von kristallisationsfähigem Kunststoffmaterial |
| GB2373500B (en) * | 2000-02-04 | 2004-12-15 | Aeomica Inc | Methods and apparatus for predicting, confirming, and displaying functional information derived from genomic sequence |
| WO2002008262A2 (en) * | 2000-07-26 | 2002-01-31 | Stanford University | Bstp-5 proteins and related reagents and methods of use thereof |
| WO2002050103A2 (en) | 2000-12-20 | 2002-06-27 | Glaxosmithkline Biologicals S.A. | Tumour-related antigens |
| WO2002078516A2 (en) | 2001-03-30 | 2002-10-10 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of cancer |
| US6867283B2 (en) | 2001-05-16 | 2005-03-15 | Technion Research & Development Foundation Ltd. | Peptides capable of binding to MHC molecules, cells presenting such peptides, and pharmaceutical compositions comprising such peptides and/or cells |
| US7049413B2 (en) * | 2001-05-18 | 2006-05-23 | Ludwig Institute For Cancer Research | MAGE-A3 peptides presented by HLA class II molecules |
| AU2002322280A1 (en) * | 2001-06-21 | 2003-01-21 | Millennium Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer |
| CA2457065A1 (en) * | 2001-08-13 | 2003-02-27 | Dana-Farber Cancer Institute, Inc. | Periostin-based diagnostic assays |
| US6906036B2 (en) * | 2001-08-16 | 2005-06-14 | Kimberly-Clark Worldwide, Inc. | Anti-aging and wound healing compounds |
| WO2003030836A2 (en) * | 2001-10-12 | 2003-04-17 | Case Western Reserve University | Neuronal regeneration |
| AU2003215244A1 (en) * | 2002-02-14 | 2003-09-04 | Curagen Corporation | Complexes and methods of using same |
| US20030194704A1 (en) * | 2002-04-03 | 2003-10-16 | Penn Sharron Gaynor | Human genome-derived single exon nucleic acid probes useful for gene expression analysis two |
| WO2004014867A2 (en) * | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Matrix metalloproteinase inhibitors and methods for identification of lead compounds |
| CA2500687A1 (en) * | 2002-10-02 | 2004-04-15 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
| EP1560597A4 (en) * | 2002-10-29 | 2007-06-27 | Pharmacia Corp | DIFFERENTIALLY EXPRESSED GENES INVOLVED IN CANCER, POLYPEPTIDES CODED THEREWITH, AND METHODS OF USING GENES |
| CN1839205B (zh) * | 2003-05-29 | 2012-05-16 | 千年药品公司 | 用于鉴定、评估、预防和治疗乳腺癌的组合物、试剂盒及方法 |
| JP2008500952A (ja) * | 2003-07-15 | 2008-01-17 | ジェノバ・リミテッド | 心臓血管障害で減少する分泌ポリペプチド種 |
| EP1757940A1 (en) | 2005-08-26 | 2007-02-28 | Cézanne S.A.S. | In vitro method for diagnosing and monitoring renal cell carcinoma (RCC) using MMP-7 as humoral biomarker for RCC |
| ATE461214T1 (de) * | 2005-09-05 | 2010-04-15 | Immatics Biotechnologies Gmbh | Tumor-assoziierte peptide, welche an unterschiedliche menschliche leukozytenantigene der klasse ii binden |
| ATE440107T1 (de) * | 2005-09-05 | 2009-09-15 | Immatics Biotechnologies Gmbh | Tumorassoziierte peptide, die hla klasse i oder ii-moleküle binden, und anti-tumor impfstoffe |
| EP1795599A1 (en) * | 2005-12-09 | 2007-06-13 | Schuler, Gerold, Prof. Dr. | Methods for generating antigen-specific effector T cells |
-
2005
- 2005-09-05 AT AT07007914T patent/ATE461214T1/de active
- 2005-09-05 PT PT07007914T patent/PT1806358E/pt unknown
- 2005-09-05 ES ES07007915T patent/ES2341295T3/es active Active
- 2005-09-05 PL PL07007914T patent/PL1806358T3/pl unknown
- 2005-09-05 ES ES07007914T patent/ES2341802T3/es active Active
- 2005-09-05 AT AT07007915T patent/ATE461215T1/de active
- 2005-09-05 EP EP05019254A patent/EP1760088B1/en not_active Not-in-force
- 2005-09-05 DK DK07007914.0T patent/DK1806358T3/da active
- 2005-09-05 SI SI200531005T patent/SI1806358T1/sl unknown
- 2005-09-05 AT AT05019254T patent/ATE388164T1/de active
- 2005-09-05 PT PT05019254T patent/PT1760088E/pt unknown
- 2005-09-05 SI SI200530994T patent/SI1806359T1/sl unknown
- 2005-09-05 DK DK07007915.7T patent/DK1806359T3/da active
- 2005-09-05 EP EP07007914A patent/EP1806358B1/en not_active Not-in-force
- 2005-09-05 DE DE602005020046T patent/DE602005020046D1/de active Active
- 2005-09-05 DK DK05019254T patent/DK1760088T3/da active
- 2005-09-05 SI SI200530167T patent/SI1760088T1/sl unknown
- 2005-09-05 PL PL07007915T patent/PL1806359T3/pl unknown
- 2005-09-05 PL PL05019254T patent/PL1760088T3/pl unknown
- 2005-09-05 PT PT07007915T patent/PT1806359E/pt unknown
- 2005-09-05 DE DE602005005196T patent/DE602005005196T2/de active Active
- 2005-09-05 ES ES05019254T patent/ES2302546T3/es active Active
- 2005-09-05 EP EP07007915A patent/EP1806359B1/en not_active Not-in-force
- 2005-09-05 DE DE602005020047T patent/DE602005020047D1/de active Active
-
2006
- 2006-09-05 WO PCT/EP2006/008642 patent/WO2007028574A2/en active Application Filing
- 2006-09-05 PT PT06791838T patent/PT1922335E/pt unknown
- 2006-09-05 EP EP09011319A patent/EP2135878B1/en active Active
- 2006-09-05 JP JP2008528438A patent/JP5627180B2/ja not_active Expired - Fee Related
- 2006-09-05 PL PL09011319T patent/PL2135878T3/pl unknown
- 2006-09-05 CN CN201510571930.7A patent/CN105440119A/zh active Pending
- 2006-09-05 ES ES06791838T patent/ES2337399T3/es active Active
- 2006-09-05 CA CA2929252A patent/CA2929252A1/en not_active Abandoned
- 2006-09-05 US US11/912,670 patent/US10196432B2/en active Active
- 2006-09-05 AU AU2006289290A patent/AU2006289290B2/en not_active Ceased
- 2006-09-05 CA CA2621389A patent/CA2621389C/en not_active Expired - Fee Related
- 2006-09-05 AT AT06791838T patent/ATE451388T1/de active
- 2006-09-05 NZ NZ566104A patent/NZ566104A/en not_active IP Right Cessation
- 2006-09-05 AT AT09011319T patent/ATE532795T1/de active
- 2006-09-05 PL PL06791838T patent/PL1922335T3/pl unknown
- 2006-09-05 NZ NZ588813A patent/NZ588813A/en not_active IP Right Cessation
- 2006-09-05 UA UAA200803825A patent/UA98295C2/ru unknown
- 2006-09-05 EA EA200800677A patent/EA013876B1/ru not_active IP Right Cessation
- 2006-09-05 EP EP06791838A patent/EP1922335B1/en active Active
- 2006-09-05 CN CN2006800383657A patent/CN101287754B/zh not_active Expired - Fee Related
- 2006-09-05 ES ES09011319T patent/ES2373907T3/es active Active
- 2006-09-05 DE DE602006011030T patent/DE602006011030D1/de active Active
- 2006-09-05 SI SI200631206T patent/SI2135878T1/sl unknown
- 2006-09-05 EP EP09011317A patent/EP2138509A1/en not_active Withdrawn
- 2006-09-05 DK DK09011319.2T patent/DK2135878T3/da active
- 2006-09-05 CN CN201210560635.8A patent/CN103059104B/zh not_active Expired - Fee Related
- 2006-09-05 PT PT09011319T patent/PT2135878E/pt unknown
- 2006-09-05 KR KR1020137002915A patent/KR101386827B1/ko not_active IP Right Cessation
- 2006-09-05 KR KR1020087008073A patent/KR101386355B1/ko not_active IP Right Cessation
- 2006-09-05 KR KR1020137002917A patent/KR101386790B1/ko not_active IP Right Cessation
- 2006-09-05 DK DK06791838.3T patent/DK1922335T3/da active
- 2006-09-05 SI SI200630566T patent/SI1922335T1/sl unknown
- 2006-09-05 BR BRPI0615462-0A patent/BRPI0615462A2/pt not_active Application Discontinuation
-
2007
- 2007-11-19 US US11/942,598 patent/US7833969B2/en active Active
- 2007-11-19 US US11/942,573 patent/US7807642B2/en active Active
- 2007-11-19 US US11/942,394 patent/US20080206216A1/en not_active Abandoned
- 2007-11-19 US US11/942,620 patent/US7833970B2/en active Active
-
2008
- 2008-04-04 NO NO20081683A patent/NO340870B1/no not_active IP Right Cessation
- 2008-05-28 CY CY20081100554T patent/CY1107973T1/el unknown
-
2010
- 2010-02-19 CY CY20101100169T patent/CY1109849T1/el unknown
- 2010-03-09 HR HR20100128T patent/HRP20100128T1/hr unknown
- 2010-05-27 CY CY20101100469T patent/CY1110051T1/el unknown
- 2010-06-11 CY CY20101100520T patent/CY1110187T1/el unknown
- 2010-10-26 AU AU2010236029A patent/AU2010236029B2/en not_active Ceased
-
2011
- 2011-12-09 CY CY20111101223T patent/CY1112186T1/el unknown
- 2011-12-30 HR HR20110981T patent/HRP20110981T1/hr unknown
-
2013
- 2013-10-02 HK HK13111197.3A patent/HK1183678A1/xx not_active IP Right Cessation
-
2015
- 2015-11-05 US US14/933,077 patent/US10618945B2/en active Active
-
2016
- 2016-07-26 HK HK16108913.9A patent/HK1220709A1/zh unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1220709A1 (zh) | 混雜地結合於人類白細胞抗原 類分子的腫瘤相關肽 | |
| HRP20110240T1 (en) | Tumor-associated peptides binding to human leukocyte antigen (hla) class i or ii molecules and related anti-cancer vaccine | |
| SI1794190T1 (sl) | Imunogeni T-pomagalni epitopi iz humanih tumornih antigenov in imunoterapevtski postopki, ki uporabljajo navedene epitope |